It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...
Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results